Your browser doesn't support javascript.
loading
Diabetes Affects Antibody Response to SARS-CoV-2 Vaccination in Older Residents of Long-term Care Facilities: Data From the GeroCovid Vax Study.
Virgilio, Enrico; Trevisan, Caterina; Abbatecola, Angela; Malara, Alba; Palmieri, Annapina; Fedele, Giorgio; Stefanelli, Paola; Leone, Pasqualina; Schiavoni, Ilaria; Maggi, Stefania; Volpato, Stefano; Antonelli Incalzi, Raffaele; Onder, Graziano.
Afiliación
  • Virgilio E; Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium.
  • Trevisan C; Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
  • Abbatecola A; Department of Medicine, University of Padua, Padua, Italy.
  • Malara A; Aging Research Center, Karolinska Institutet, Stockholm, Sweden.
  • Palmieri A; Alzheimer's Disease Day Clinic, Azienda Sanitaria Locale, Frosinone, Italy.
  • Fedele G; Associazione Nazionale Strutture Territoriali e per la Terza Età (ANASTE)-Humanitas Foundation, Rome, Italy.
  • Stefanelli P; Istituto Superiore di Sanità, Roma, Italy.
  • Leone P; Istituto Superiore di Sanità, Roma, Italy.
  • Schiavoni I; Istituto Superiore di Sanità, Roma, Italy.
  • Maggi S; Istituto Superiore di Sanità, Roma, Italy.
  • Volpato S; Istituto Superiore di Sanità, Roma, Italy.
  • Antonelli Incalzi R; Institute of Neuroscience, National Research Council, Padua, Italy.
  • Onder G; Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Diabetes Care ; 45(12): 2935-2942, 2022 12 01.
Article en En | MEDLINE | ID: mdl-36201657
OBJECTIVE: Type 2 diabetes may affect the humoral immune response after vaccination, but data concerning coronavirus disease 19 (COVID-19) vaccines are scarce. We evaluated the impact of diabetes on antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in older residents of long-term care facilities (LTCFs) and tested for differences according to antidiabetic treatment. RESEARCH DESIGN AND METHODS: For this analysis, 555 older residents of LTCFs participating in the GeroCovid Vax study were included. SARS-CoV-2 trimeric S immunoglobulin G (anti-S IgG) concentrations using chemiluminescent assays were tested before the first dose and after 2 and 6 months. The impact of diabetes on anti-S IgG levels was evaluated using linear mixed models, which included the interaction between time and presence of diabetes. A second model also considered diabetes treatment: no insulin therapy (including dietary only or use of oral antidiabetic agents) and insulin therapy (alone or in combination with oral antidiabetic agents). RESULTS: The mean age of the sample was 82.1 years, 68.1% were women, and 25.2% had diabetes. In linear mixed models, presence of diabetes was associated with lower anti-S IgG levels at 2 (ß = -0.20; 95% CI -0.34, -0.06) and 6 months (ß = -0.22; 95% CI -0.37, -0.07) after the first vaccine dose. Compared with those without diabetes, residents with diabetes not using insulin had lower IgG levels at 2- and 6-month assessments (ß = -0.24; 95% CI -0.43, -0.05 and ß = -0.30; 95% CI -0.50, -0.10, respectively), whereas no differences were observed for those using insulin. CONCLUSIONS: Older residents of LTCFs with diabetes tended to have weaker antibody response to COVID-19 vaccination. Insulin treatment might buffer this effect and establish humoral immunity similar to that in individuals without diabetes.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / COVID-19 Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Diabetes Care Año: 2022 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / COVID-19 Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Diabetes Care Año: 2022 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos